<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="114248">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01820767</url>
  </required_header>
  <id_info>
    <org_study_id>SENPARIC-2011-01</org_study_id>
    <nct_id>NCT01820767</nct_id>
  </id_info>
  <brief_title>Paricalcitol Over Inflammatory Parameters on Chronical Kidney Disease Patients</brief_title>
  <acronym>SENPARIC</acronym>
  <official_title>Action of Paricalcitol Over Inflammatory Parameters on Chronical Kidney Disease (Stadium Vd)Patients Bearing Tunnelized Vascular Catheters for Haemodialysis (SENPARIC Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ricardo Mouzo Mirco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital El Bierzo</source>
  <oversight_info>
    <authority>Spain: Spanish Agency of Medicines</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Use of Paricalcitol in stage Vd Chronic Kidney Disease patients, over the effect of
      inflammatory and oxidative stress parameters.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Use of Paricalcitol in stage Vd Chronic Kidney Disease patients using a permanent catheter
      due to haemodialysis; over the effect of inflammatory and oxidative stress parameters. This
      study uses paricalcitol (vitamin D) versus atorvastatin versus paricalcitol plus
      atorvastatin treatments.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">November 2013</completion_date>
  <primary_completion_date type="Anticipated">June 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Concentration of oxidative enzymes and VCAM-1, ICAM-1 and TNF-α values in blood</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluation of Oxidative stress and inflammative parameters before and after the paricalcitol intake.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progress of Nutritional and anaemia parameters</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of patients showing an improvement between the values os nutritional and anaemia parameters before and after the paricalcitol intake.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Erythropoetin requirement variations</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of patients showing progress after paricalcitol intake on erythropoetin variations.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Paricalcitol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SUBGROUP 1 (G1): Oral Paricalcitol= dosis Trial Priority Index mcg/100, 3 days a week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paricalcitol, Atorvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SUBGROUP 2 (G2): Paricalcitol (same dosis than G1) + Atorvastatin (1 daily dosis of 20 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atorvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SUBGROUP 3 (G3): Atorvastatin  (same dosis than G2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paricalcitol</intervention_name>
    <description>oral Paricalcitol. 3 days per week, the same day as haemodialysis is done, during 12 weeks.</description>
    <arm_group_label>Paricalcitol</arm_group_label>
    <other_name>Group 1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paricalcitol, atorvastatin</intervention_name>
    <description>Oral Paricalcitol. 3 days a week, the same day as haemodialysis, during 12 weeks.
Atorvastatin: 20 mg/day oral (1 intake) during 12 weeks.</description>
    <arm_group_label>Paricalcitol, Atorvastatin</arm_group_label>
    <other_name>G2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>Atorvastatin: 20 mg/day oral (1 take) during 12 weeks</description>
    <arm_group_label>Atorvastatin</arm_group_label>
    <other_name>G3</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Vd CKD patients using haemodialysis during 3 or more months.

          -  Patients attached with a permanent haemodialysis catheter since, at last 6 month
             before the beginning of the study.

          -  Stabilized Kt, over 45 litres on both sexs.

          -  Using a previous atorvastatin treatment.

          -  Patients without infectious processes or active inflammatory process during an 8 week
             period before the beginning of the study.

          -  2 Consecutive PTH &lt; than 400 pg/ml; Ca&lt;10.2 and P &lt;7.0 mg/dl.

        Exclusion Criteria:

          -  Patients &gt; 18 years.

          -  Pregnant women.

          -  Patients who have been hospitalized 4 weeks before the beginning of the treatment.

          -  Immunosuppressor intake.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ricardo Mouzo Mirco, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital El Bierzo, Fuentesnuevas Ponferrada</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ricardo Mouzo Mirco, MD</last_name>
    <phone>+34 987 455 200</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Francisco Borrás Mandrión, CRA</last_name>
    <phone>+34 91 29489410</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital El Bierzo. Servicio de Nefrología.</name>
      <address>
        <city>Ponferrada</city>
        <state>(León).</state>
        <zip>24411,</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ricardo Mouzo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de León</name>
      <address>
        <city>León</city>
        <zip>24008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Benjamin De León, MD</last_name>
      <phone>987 23 74 00</phone>
    </contact>
    <investigator>
      <last_name>Benjamín De León, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mario Prieto, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <lastchanged_date>March 26, 2013</lastchanged_date>
  <firstreceived_date>March 19, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital El Bierzo</investigator_affiliation>
    <investigator_full_name>Ricardo Mouzo Mirco</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Chronic Kidney Disease</keyword>
  <keyword>Vd-stadium.</keyword>
  <keyword>Inflammatory patterns</keyword>
  <keyword>Paricalcitol</keyword>
  <keyword>Atorvastatin</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atorvastatin</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
